
<html>
        <meta charset="UTF-8">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        <link rel="icon" type="image/x-icon" href="../images/favicon.ico">
        <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.1.1/css/all.min.css">
        <title id="title">News'n'Clues - HEALTH Article Summaries - 2025-05-05</title>
        <script src="https://cdn.tailwindcss.com"></script>
        <style>
            .menu { color: #444444; }
            .copyright { margin: 0 auto; }
            p { font-family: serif; }
            body {  background-color: #2c2c2c; font-family: Arial, sans-serif; font-size: 20px; color: #f4f4f4;  }
            a { text-decoration: none; color: #f4f4f4; }
            .section { margin-bottom: 20px; }
            .heading {
                font-size: 2rem;
                font-weight: bold;
                background: linear-gradient(90deg, #fc4535, #1a6198);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                text-shadow: 1px 1px 2px rgba(0, 0, 0, 0.2);
                line-height: 1.3; /* Prevents letters from being cut off */
                padding-bottom: 5px; /* Ensures space below the text */
                margin: 30px;
            }
            .hidden {
                display: none;
            }            
            
        </style>
    </head>
    <body>
        <div id="banner" class="w-full">
            <img src="../images/banner.jpg" alt="News Banner">
        </div>

        <div id="title" class="w-full flex items-center" style="background-color: #fc4535;">
          <a href="../index.html"><img src="../images/logo.jpg" alt="News Logo" class="h-auto"></a>
          <div class="flex-grow text-center">
              <div id="title_heading" class="text-4xl font-bold mb-4" style="color:#1a6198;">Article Summaries</div>
          </div>
        </div>
        <div id='category_heading' class="section text-center heading">
            HEALTH
        </div>
        <div id="articles">
            
                <div id='article_title' class='text-3xl text-gray-300 leading-tight'>
                    <a target='_blank' href='https://www.news-medical.net/news/20250505/TM6SF2-gut-specific-knockout-aggravates-liver-lipid-accumulation-in-MASLD-mice.aspx'>TM6SF2 gut-specific knockout aggravates liver lipid accumulation in MASLD mice</a>
                </div>
                <div id='article_attribution'  style='mb-1'>
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Source:</span> {'href': 'https://www.news-medical.net', 'title': 'News-Medical'}&nbsp;&nbsp;&nbsp;
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Published:</span> 2025-05-05 14:30:00
                    <i class="fas fa-chevron-down expand-icon text-gray-500" aria-hidden="true"></i>
                </div>
                <p class='hidden' class='text-gray-500'>This study aimed to explore the role of TM6SF2 in high-fat diet (HFD)-induced MASLD through the gut-liver axis. The TM6SF2 gut-specific knockout (TM6SF2 GKO) mouse was constructed using CRISPR/Cas9 technology. TM6SF2 GKO and wild-type (CON) mice were fed either a HFD or a control diet for 16 weeks to induce MASLD. Blood, liver, and intestinal lipid content, as well as gut microbiota and serum metabolites, were then analyzed. The gut microbiota of HFD-fed TM6SF2 GKO mice exhibited a decreased Firmicutes/Bacteroidetes ratio compared to HFD-fed CON mice. The HFD also reduced the diversity and abundance of the microbiota and altered its composition.Aspartate aminotransferase, alanineaminotransferase, and total cholesterol levels were higher in HFD-fed TM6SF2 GKO mice compared to CON mice, while triglyceride levels were lower. Serum metabolite analysis revealed that HFD-fed TM6SF2 GKO mice had an increase in the expression of 17 metabolites (e.g., LPC [18:0/0-0]) and a decrease in 22 metabolites (e.g., benzene sulfate). The differential metabolites of LPC (18:0/0-0) may serve as HFD-fed TM6SF2 serum biomarkers, leading to MASLD exacerbation in GKO mice. TM6SF2 may play an important role in regulating intestinal flora and the progression of MASLD through the gut-liver axis. Intestinal Depletion of TM6SF2 Exacerbates High-fat Diet-induced Metabolic Dysfunction-associated Steatotic Liver Disease through the Gut-liver Axis. Learn how experts are advancing benzodiazepine analysis and detection using insights from the lab. Emily Lee, Karen Lau and Dr. Patrick Sears Explore how the Radian ASAP mass spectrometer is being used to streamline and enhance seized drug screening. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. Please check the box above to proceed. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.</p>
                <br/>
                

                <div id='article_title' class='text-3xl text-gray-300 leading-tight'>
                    <a target='_blank' href='https://reference.medscape.com/viewarticle/mechanisms-opioid-drug-interactions-beyond-additive-cns-and-2025a1000akh'>Mechanisms of Opioid Drug Interactions: Beyond Additive CNS and Respiratory Depression</a>
                </div>
                <div id='article_attribution'  style='mb-1'>
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Source:</span> {'href': 'https://reference.medscape.com', 'title': 'Medscape'}&nbsp;&nbsp;&nbsp;
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Published:</span> 2025-05-05 14:18:15
                    <i class="fas fa-chevron-down expand-icon text-gray-500" aria-hidden="true"></i>
                </div>
                <p class='hidden' class='text-gray-500'>Disclosure: Michelle Vermeulen, PharmD, has disclosed no relevant financial relationships. Opioid medications can play an essential role in managing pain, yet their use may pose significant risks, especially when interacting with other drugs. A particularly dangerous combination is the concurrent use of benzodiazepines, opioids, and muscle relaxants, a triad that significantly increases the risk for respiratory depression and overdose. Although healthcare providers are generally aware of this risk, it is important to recognize that the landscape of opioid drug interactions extends beyond these well-known concerns. The presentation may vary from mild adverse effects including anxiety, hypertension, tachycardia, hyperreflexia, and diarrhea to severe, life-threatening toxicity. Serotonin syndrome may be precipitated by use of a single serotonergic drug or as a drug interaction between two or more serotonergic agents. The combination of a monoamine oxidase inhibitor (MAOI) and another serotonergic drug, typically a selective serotonin reuptake inhibitor (SSRI), has resulted in the most severe cases of serotonin syndrome reported in the literature, whereas concomitant use of an SSRI and tramadol is the most frequent cause of serotonin syndrome. Opioids contribute to the development of serotonin syndrome through several mechanisms. Although the risk for serotonin syndrome is not a contraindication to use of opioids with other serotonergic drugs, prescribers should frequently monitor patients for the development of symptoms, particularly during treatment initiation and dose titration. Discontinue all serotonergic agents if serotonin syndrome is suspected. CYP450 enzymes are responsible for the metabolism of many drugs, including opioids. These enzymes also play a significant role in the biotransformation of several opioids. CYP3A4 and CYP2D6 inhibitors commonly include macrolide antibiotics, azole antifungal agents, antiretroviral protease inhibitors, certain SSRIs (fluoxetine, paroxetine), and bupropion, among many others. When prescribing a CYP3A4 or CYP2D6 inhibitor with opioids dependent on these enzymes for metabolism, consider a reduced opioid dose until stable effects are achieved. Although CYP450 inhibitors typically increase the concentration of drugs, codeine is metabolized by CYP2D6 into its active form, morphine, which is responsible for its analgesic effects. When codeine sulfate tablets are used concurrently with CYP2D6 inhibitors, the plasma concentration of codeine may increase; however, the formation of morphine is inhibited, leading to a decrease in its plasma concentration. This can result in reduced analgesic efficacy and may even precipitate symptoms of opioid withdrawal, particularly if a CYP2D6 inhibitor is introduced after a stable dose of codeine has been established. Drug-induced QT prolongation increases the risk for torsades de pointes, a potentially fatal ventricular arrhythmia. However, many other drugs have the ability to prolong the QT interval, including certain opioids, such as methadone, buprenorphine, and tramadol. The risk for QT prolongation can be exacerbated by concomitant use of other medications that also prolong the QT interval, such as certain antidepressants, antipsychotics, and antiarrhythmics. These drug interactions can lead to additive effects, heightening the risk for cardiovascular complications. Clinicians must be vigilant in monitoring patients who are prescribed opioids, especially those with preexisting cardiac conditions or those taking multiple medications that affect the QT interval. Although opioid medications are invaluable tools in pain management, their potential for harmful drug interactions necessitates a comprehensive understanding of the associated risks. By fostering awareness of the complexities surrounding opioid use and its interactions, clinicians can enhance patient safety, optimize therapeutic outcomes, and mitigate the risks associated with these powerful medications. Ultimately, a proactive approach to managing opioid therapy will contribute to more effective pain management while minimizing the potential for serious complications.</p>
                <br/>
                

                <div id='article_title' class='text-3xl text-gray-300 leading-tight'>
                    <a target='_blank' href='https://www.news-medical.net/news/20250505/New-biomarkers-and-therapeutic-targets-identified-for-abdominal-aortic-aneurysm.aspx'>New biomarkers and therapeutic targets identified for abdominal aortic aneurysm</a>
                </div>
                <div id='article_attribution'  style='mb-1'>
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Source:</span> {'href': 'https://www.news-medical.net', 'title': 'News-Medical'}&nbsp;&nbsp;&nbsp;
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Published:</span> 2025-05-05 14:11:00
                    <i class="fas fa-chevron-down expand-icon text-gray-500" aria-hidden="true"></i>
                </div>
                <p class='hidden' class='text-gray-500'>Announcing a new article publication for Cardiovascular Innovations and Applications journal. This article aimed to identify molecular candidates to serve as diagnostic biomarkers and therapeutic targets for abdominal aortic aneurysm (AAA). Gene expression profiles at the single-cell level were validated through in vitro experiments. RT-qPCR validated a significant decrease in mRNA levels of BTC and KLF15 in VSMCs after angiotensin II administration. All-trans retinal, which interacts with BTC, was identified as a potential drug for AAA treatment. RAD21 might be a common TF driving both BTC and KLF15 expression. Two biomarkers and a potential therapeutic agent for AAA were identified, thus enhancing understanding of the molecular mechanisms underlying the disease and offering novel strategies for its clinical management. Identification of BTC and KLF15 in Vascular Smooth Muscle Cells as Key Biomarkers for Abdominal Aortic Aneurysm via Machine Learning and In Vitro Experiments. Learn how experts are advancing benzodiazepine analysis and detection using insights from the lab. Emily Lee, Karen Lau and Dr. Patrick Sears Explore how the Radian ASAP mass spectrometer is being used to streamline and enhance seized drug screening. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. Please check the box above to proceed. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.</p>
                <br/>
                

                <div id='article_title' class='text-3xl text-gray-300 leading-tight'>
                    <a target='_blank' href='https://www.news-medical.net/news/20250505/Asthma-related-emergency-visits-increase-during-wildfire-smoke-events-in-Ontario.aspx'>Asthma-related emergency visits increase during wildfire smoke events in Ontario</a>
                </div>
                <div id='article_attribution'  style='mb-1'>
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Source:</span> {'href': 'https://www.news-medical.net', 'title': 'News-Medical'}&nbsp;&nbsp;&nbsp;
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Published:</span> 2025-05-05 14:07:00
                    <i class="fas fa-chevron-down expand-icon text-gray-500" aria-hidden="true"></i>
                </div>
                <p class='hidden' class='text-gray-500'>Canada experienced the most destructive wildfire season to date in 2023, with difficult-to-control fires across the country, including 29 mega-fires. One fire in Quebec, the province's largest-ever wildfire, extended 1.2 million acres. "The unprecedented wildfires of 2023 are a wake-up call that wildfires - a persistent feature of Canada's landscape - are becoming more intense and prolonged in a changing climate, affecting millions of people," writes Dr. Hong Chen, a scientist with Health Canada, ICES, and Public Health Ontario, with coauthors. In early June, Ontario had some of the world's worst air quality from wildfires in the neighbouring province of Quebec. To understand the impact on health, researchers conducted a study, analyzing ED visits throughout the period from 8 weeks before a major wildfire event in early June until July 31, 2023, 4 weeks after a second fire that resulted in smoke. They found daily increases of 11% to 24% in asthma-related emergency department visits over the first episode, continuing up to 6 days after it ended. "Possible explanations [of the lack of effect during the second episode] include extended protective effects of preventive medications prescribed during the first episode, increased supply and use of medications (e.g., caregiver administration of maintenance medication to children), or improved behavioural adaptations to minimize exposure in keeping with air-quality advisories, such as staying indoors and using air filters." As wildfires are a major environmental risk factor around the world and are increasing in frequency and severity, the researchers note that more research is needed to better understand their impact on health and how to mitigate health effects. "The biggest impact of wildfire smoke is on acute respiratory morbidity, where its effects are consistently greater than those of air pollution from other sources," writes Dr. Sarah Henderson from the BC Centre for Disease Control, in a related commentary https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250510. "Less clear associations have been shown for a much wider range of acute health outcomes, including cognition, diabetic control, and mental health, among many others." Dr. Henderson highlights that wildfire smoke frequently affects air quality in the west and calls for Canada to develop a consistent approach to reducing indoor and outdoor exposures. Impact of the 2023 wildfire smoke episodes in Ontario, Canada, on asthma and other health outcomes: an interrupted time-series analysis. Learn how experts are advancing benzodiazepine analysis and detection using insights from the lab. Emily Lee, Karen Lau and Dr. Patrick Sears Explore how the Radian ASAP mass spectrometer is being used to streamline and enhance seized drug screening. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. Please check the box above to proceed. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.</p>
                <br/>
                

                <div id='article_title' class='text-3xl text-gray-300 leading-tight'>
                    <a target='_blank' href='https://www.news-medical.net/news/20250505/Boosting-glucose-metabolism-in-glial-cells-reduces-neurodegeneration-in-fruit-flies.aspx'>Boosting glucose metabolism in glial cells reduces neurodegeneration in fruit flies</a>
                </div>
                <div id='article_attribution'  style='mb-1'>
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Source:</span> {'href': 'https://www.news-medical.net', 'title': 'News-Medical'}&nbsp;&nbsp;&nbsp;
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Published:</span> 2025-05-05 13:09:00
                    <i class="fas fa-chevron-down expand-icon text-gray-500" aria-hidden="true"></i>
                </div>
                <p class='hidden' class='text-gray-500'>Researchers from Tokyo Metropolitan University have discovered that impaired glucose metabolism in glial cells, a type of cell in our nervous system, plays a key role in the degeneration caused by Alzheimer's disease. Using fruit fly retinas, they showed that promoting glucose metabolism in glial cells with tau protein build-up, like in Alzheimer's patients, helps relieve inflammation and photoreceptor degeneration. Their findings present an exciting new therapeutic target for treating neurodegenerative conditions. Alzheimer's disease (AD) is the world's leading cause of dementia among older people and continues to have a devastating impact on people's quality of life. Scientists are working against the clock to unravel the vast network of mechanisms by which AD affects our nervous system. We know, for example, that AD is characterized by a build-up of tau protein inside cells, but the ways in which this leads to neurodegeneration are not yet fully understood. A team led by Professor Kanae Ando of Tokyo Metropolitan University have turned their attention to how tau protein build-up affects glial cells, non-neuronal cells in our central nervous system that help support, feed, and protect neurons. Importantly, the ways in which glial cells work have a lot do with what happens in AD patients. For example, glial cells are known to clear away abnormal build-up of protein, accompanied by an inflammatory response; neuroinflammation is a core pathology of AD. They play an important role in helping neurons stay fueled by metabolizing glucose; a drastic drop in brain glucose metabolism is another feature of AD patients. However, the relationship between changes to glial cell glucose metabolism and tau protein build-up was not known. Using Drosophila fruit flies as a model, firstly the team showed that flies modified to have a tau-protein build-up in the retina showed neurodegeneration, swelling in nearby regions, and the formation of abnormal inclusions. They were able to show that the latter of these was caused by glial cells being abnormally active. This shows that tau-protein build-up causes glial cells to suffer from a significant drop in glucose metabolism. The team propose that glial glucose metabolism might be a new target for novel therapies for neurodegenerative conditions. Diseases like Parkinson's, for example, are also characterized by neuroinflammation. Any advances which might cure, prevent, or even slow down the onset of any of these conditions promise to have a game-changing impact on human society. Learn how experts are advancing benzodiazepine analysis and detection using insights from the lab. Explore how the Radian ASAP mass spectrometer is being used to streamline and enhance seized drug screening. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.</p>
                <br/>
                

                <div id='article_title' class='text-3xl text-gray-300 leading-tight'>
                    <a target='_blank' href='https://www.news-medical.net/news/20250505/CEPI-and-University-of-Bergen-collaborate-on-global-vaccine-mapping-project.aspx'>CEPI and University of Bergen collaborate on global vaccine mapping project</a>
                </div>
                <div id='article_attribution'  style='mb-1'>
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Source:</span> {'href': 'https://www.news-medical.net', 'title': 'News-Medical'}&nbsp;&nbsp;&nbsp;
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Published:</span> 2025-05-05 13:05:00
                    <i class="fas fa-chevron-down expand-icon text-gray-500" aria-hidden="true"></i>
                </div>
                <p class='hidden' class='text-gray-500'>Supported by CEPI funding of up to $ 1.5 million over three years, researchers at Norway's University of Bergen will maintain an up-to-date overview of every vaccine candidate being developed around the globe for CEPI's priority pathogens as well as other emerging viral threats identified by CEPI. This comprehensive mapping of the infectious disease vaccine pipeline will help CEPI to monitor and evaluate global R&D progress, and to spot gaps and opportunities to enhance its own portfolio of vaccines. Access to comprehensive data about the global vaccine development landscape is vital to the success of CEPI's mission. This new partnership with the University of Bergen will provide CEPI with greater visibility of the vaccine R&D pipeline around the world and help us to make well-informed choices when selecting and investing in new vaccine candidates and technologies." Prof. Rebecca Cox at the University of Bergen says that "the recent COVID-19 and influenza pandemics have shown us that our ability to rapidly develop, and deploy vaccines is critical for global health security. As new epidemic threats emerge, understanding where and how to invest in vaccine research and development is vital and we are delighted to partner with CEPI to conduct this important work for future pandemic preparedness." The University of Bergen has been spearheading research into influenza and coronavirus vaccines for many years, generating data that inform the global health community. Learn how experts are advancing benzodiazepine analysis and detection using insights from the lab. Explore how the Radian ASAP mass spectrometer is being used to streamline and enhance seized drug screening. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. Please check the box above to proceed. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.</p>
                <br/>
                

                <div id='article_title' class='text-3xl text-gray-300 leading-tight'>
                    <a target='_blank' href='https://www.news-medical.net/news/20250505/Anal-cancer-rates-increasing-among-older-white-and-Hispanic-women-in-the-US.aspx'>Anal cancer rates increasing among older white and Hispanic women in the U.S.</a>
                </div>
                <div id='article_attribution'  style='mb-1'>
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Source:</span> {'href': 'https://www.news-medical.net', 'title': 'News-Medical'}&nbsp;&nbsp;&nbsp;
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Published:</span> 2025-05-05 12:33:00
                    <i class="fas fa-chevron-down expand-icon text-gray-500" aria-hidden="true"></i>
                </div>
                <p class='hidden' class='text-gray-500'>Anal cancer has been steadily increasing in the United States, with the biggest jumps among older women, especially white and Hispanic women - a shift that challenges assumptions about high-risk groups and who should be screened, according to a study to be presented today at Digestive Disease Week® (DDW) 2025. Rates of anal cancer are rising fastest among white and Hispanic women over 65 - groups not traditionally considered high risk. While the exact reasons behind this trend remain unclear, most older women were beyond the recommended age for human papillomavirus vaccination when it first became widely available." Ashley Robinson, MD, lead author, second-year internal medicine resident at Advocate Lutheran General Hospital Human papillomavirus, known as HPV, causes 90% of anal cancers. Anal cancers increased fastest among white women over 65, who saw a 4.3% increase during the five-year study period, reaching 11.4 cases per 100,000 in 2021. Hispanic women over age 65 had the second-highest rate of anal cancer, with 7.5 cases per 100,000 people in 2021 and a slower annual increase of 1.7%. "It's crucial that we promote HPV vaccination as a key tool for preventing anal cancer, while also keeping health care providers informed as screening guidelines evolve," Dr. Robinson said. Still considered rare, anal cancer makes up approximately 1% of all gastrointestinal cancers, with more than 90% of cases linked to chronic HPV infection. While screening for anal HPV, dysplasia and cancer is recommended for high-risk groups - identified as individuals with HIV, bone marrow transplant recipients and other immunocompromised populations - older women addressed in this study are not included. Robinson will present data from the study, "Analysis of temporal trends in anal cancer incidence by sex, age, and ethnicity," abstract 76, at 8:48 a.m. PDT, Saturday, May 3. Learn how experts are advancing benzodiazepine analysis and detection using insights from the lab. Explore how the Radian ASAP mass spectrometer is being used to streamline and enhance seized drug screening. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.</p>
                <br/>
                

                <div id='article_title' class='text-3xl text-gray-300 leading-tight'>
                    <a target='_blank' href='https://www.news-medical.net/news/20250505/Study-shows-the-connection-between-language-disorders-and-handedness.aspx'>Study shows the connection between language disorders and handedness</a>
                </div>
                <div id='article_attribution'  style='mb-1'>
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Source:</span> {'href': 'https://www.news-medical.net', 'title': 'News-Medical'}&nbsp;&nbsp;&nbsp;
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Published:</span> 2025-05-05 11:00:00
                    <i class="fas fa-chevron-down expand-icon text-gray-500" aria-hidden="true"></i>
                </div>
                <p class='hidden' class='text-gray-500'>Linguistic symptoms and an onset early in life: Disorders to which this applies are frequently associated with left-handedness resp. mixed-handedness are strikingly common in patients with certain neurological disorders such as autism spectrum disorders is a frequently reported observation in medical practice. The reason why handedness is associated with these disorders is probably because both are affected by processes in early brain development. Various studies have explored this link for individual disorders and have sometimes been able to show it, and sometimes not. A meta-analysis carried out by an international research team from Bochum, Hamburg, Nijmegen and Athens shows that left and mixed-handedness is particularly common in people who suffer from a disorder that manifests itself early in life and is associated with linguistic symptoms. They published their findings in the journal Psychological Bulletin on May, 2, 2025. The research team re-evaluated existing meta-analyses from a new perspective. We suspected that left- and mixed- handedness could be associated with disorders whose symptoms are related to language. Language, like handedness, has a very one-sided location in the brain, so it stands to reason that the development of both and their disorders could be linked." Dr. Julian Packheiser, Institute of Cognitive Neuroscience, Ruhr University Bochum The researchers also suspected that left-handedness and mixed-handedness could be associated with diseases that occur very early in life. "Both hypotheses have been confirmed," says Professor Sebastian Ocklenburg from the Medical School Hamburg. For example, left-handedness and mixed-handedness are statistically significantly more common in people with dyslexia - a reading disorder - than in healthy individuals. Autism, which in severe cases is accompanied by communication disorders, and schizophrenia, in which patients sometimes hear voices, are also associated with both linguistic symptoms and a higher incidence of left-handedness and mixed-handedness. "In people with depression, which on average occurs around the age of 30, we couldn't show any connection," points out Julian Packheiser. The researchers believe this is evidence that handedness and various neuronal developmental disorders are influenced by partially overlapping processes in early brain development. Learn how experts are advancing benzodiazepine analysis and detection using insights from the lab. Emily Lee, Karen Lau and Dr. Patrick Sears Explore how the Radian ASAP mass spectrometer is being used to streamline and enhance seized drug screening. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.</p>
                <br/>
                

                <div id='article_title' class='text-3xl text-gray-300 leading-tight'>
                    <a target='_blank' href='https://www.news-medical.net/news/20250505/Trump-teame28099s-24500-million-bet-on-old-vaccine-technology-puzzles-scientists.aspx'>Trump team's $500 million bet on old vaccine technology puzzles scientists</a>
                </div>
                <div id='article_attribution'  style='mb-1'>
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Source:</span> {'href': 'https://www.news-medical.net', 'title': 'News-Medical'}&nbsp;&nbsp;&nbsp;
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Published:</span> 2025-05-05 10:51:00
                    <i class="fas fa-chevron-down expand-icon text-gray-500" aria-hidden="true"></i>
                </div>
                <p class='hidden' class='text-gray-500'>The Trump administration's unprecedented $500 million grant for a broadly protective flu shot has confounded vaccine and pandemic preparedness experts, who said the project was in early stages, relied on old technology, and was just one of more than 200 such efforts. Health and Human Services Secretary Robert F. Kennedy Jr. shifted the money from a pandemic preparedness fund to a vaccine development program led by two scientists whom the administration recently named to senior positions at the National Institutes of Health. While some experts were pleased that Kennedy had supported any vaccine project, they said the May 1 announcement contravened sound scientific policy, appeared arbitrary, and raised the kinds of questions about conflicts of interest that have dogged many of President Donald Trump's actions. Focusing vast resources on a single vaccine candidate "is a little like going to the Kentucky Derby and putting all your money on one horse," said William Schaffner, a Vanderbilt University professor and past president of the National Foundation for Infectious Diseases. "In science we normally put money on a number of different horses because we can't be entirely sure who's going to win." "This is not a next-generation vaccine," said Rick Bright, who led HHS' Biomedical Advanced Research and Development Authority, or BARDA, in the first Trump administration. The vaccine is being developed at the National Institute for Allergy and Infectious Diseases by Jeffery Taubenberger, whom Trump named as acting chief of the institute in late April, and his colleague Matthew Memoli, a critic of U.S. covid-19 policy whom Trump picked to lead the NIH until April 1, when Jay Bhattacharya took office. Taubenberger gained fame as an Armed Forces Institute of Pathology scientist in 1997 when his lab sequenced the genome of the 1918 pandemic influenza virus, using tissue samples from U.S. troops who died in that plague. In a May 1 news release, HHS called the Taubenberger-Memoli vaccine initiative "Generation Gold Standard," saying it represented "a decisive shift toward transparency, effectiveness, and comprehensive preparedness." But the NIH vaccine-makers' goal of creating a shot that protects against multiple or all strains of influenza — currently vaccines must be given each year to account for shifts in the virus — is not new. Then-NIAID Director Anthony Fauci launched a network of academic researchers in pursuit of a broadly protective flu vaccine in 2019. Many use newer technologies, and some are at more advanced stages of human testing than the Taubenberger vaccine, whose approach appears basically the same as the one used in flu vaccines starting in 1944, Bright said. In the news release, HHS described the vaccine as "in advanced trials" and said it would induce "robust" responses and "long-lasting protection." But Taubenberger and his colleagues haven't published a complete human study of the vaccine yet. For Operation Warp Speed, which led to the creation of the covid vaccine during Trump's first term, government scientists reviewed detailed plans and data from academic and commercial laboratories vying for federal money, said Greg Poland, a flu expert and president of the Atria Health Academy of Science and Medicine. "If that's happening here, it's opaque to me," he said. When asked what data beyond its press release supported the decision, HHS spokesperson Andrew Nixon pointed to the agency's one-page statement. Asked whether the decision would curtail funding for the Fauci-created consortium or other universal vaccine approaches, Nixon did not specifically respond. "Generation Gold Standard is the most promising," he said in an email. Taubenberger did not respond to a request for comment. Nixon and NIH spokesperson Amanda Fine did not respond to requests for an interview with Taubenberger or Memoli. While any vaccine would eventually have to be made commercially, NIH involvement through more stages of development could give the government greater influence on any vaccine's eventual price, Schaffner said. Their vaccine is made by inactivating influenza viruses with a carcinogenic chemical called beta-propiolactone. This whole-virus inactivation method, mostly using other chemicals, was the standard way to make flu vaccines into the 1970s, when it was modified, partly because whole-virus vaccines caused high fevers or even seizures in children. The limited published data from the Taubenberger vaccine, from an initial safety trial involving 45 patients, showed no major side effects. Paul Friedrichs, a retired Air Force general who led the Office of Pandemic Preparedness and Response Policy in President Joe Biden's White House, said that "giving $500 million upfront with very little data to support it is unlike anything I've ever seen." "The technology for developing vaccines has tremendously evolved over many decades," Friedrichs said. "Why would we go back to an approach historically associated with greater or more frequent adverse events?" Most of that money was earmarked to support advanced research on covid and other viral vaccines, including those protecting against emerging diseases. Ted Ross, director of global vaccine development at the Cleveland Clinic, said he was "happy to see them investing in respiratory vaccines, including a universal flu vaccine, with all the programs they've been cutting." "But I don't think this is the only approach," Ross said. His team, part of the NIAID-funded flu vaccine consortium, is using artificial intelligence and computer modeling to design vaccines that produce the broadest immunity to influenza, including seasonal and pandemic strains. More than 1,200 NIH employees have been fired, and many researchers, including Ross, are in limbo. His lab is close to testing a candidate vaccine on people, Ross said, while waiting to find out about its NIH funding. "I'm not sure whether my contract is on the chopping block," he said. This article was reprinted from khn.org, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF - the independent source for health policy research, polling, and journalism. Learn how experts are advancing benzodiazepine analysis and detection using insights from the lab. Explore how the Radian ASAP mass spectrometer is being used to streamline and enhance seized drug screening. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.</p>
                <br/>
                

                <div id='article_title' class='text-3xl text-gray-300 leading-tight'>
                    <a target='_blank' href='https://www.news-medical.net/news/20250504/Can-your-diet-affect-fertility-Gut-linked-dietary-score-reveals-surprising-risk-pattern.aspx'>Can your diet affect fertility? Gut-linked dietary score reveals surprising risk pattern</a>
                </div>
                <div id='article_attribution'  style='mb-1'>
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Source:</span> {'href': 'https://www.news-medical.net', 'title': 'News-Medical'}&nbsp;&nbsp;&nbsp;
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Published:</span> 2025-05-05 01:45:00
                    <i class="fas fa-chevron-down expand-icon text-gray-500" aria-hidden="true"></i>
                </div>
                <p class='hidden' class='text-gray-500'>A new study reveals that while healthier gut-friendly diets lower infertility risk, going beyond a certain dietary threshold may reverse the benefit, underscoring the need for balance in nutritional planning. Study findings demonstrated a complex non-linear association between DI-GM scores and infertility. While lower scores generally correlated with higher infertility risk, the analysis revealed an inflection point: above a certain DI-GM score (specifically, a score of 8), the risk of infertility paradoxically increased. These findings suggest that future gut microbiota research and dietary interventions may help address infertility's silent pandemic, emphasizing the need for a balanced approach rather than simply maximizing DI-GM. Infertility, the medical condition characterized by an individual's inability to achieve a clinical pregnancy even following 12 months of frequent unprotected sex, is a growing global public health concern. Current estimates report that 12.5% of all couples of childbearing age suffer from the condition, with genetic, lifestyle, and environmental factors implicated in its incidence. Alarmingly, several health agencies classify infertility as the third most important threat to public health, following cardiovascular diseases (CVDs) and cancers. “Common etiologies include ovulatory dysfunction, endometriosis, polycystic ovary syndrome (PCOS), fallopian tube abnormalities, and immunological disorders.” Recent research on female infertility has highlighted diet as a potentially modifiable healthy behavior with modulatory impacts. The strong influence of dietary patterns over gut microbiota composition and performance suggests dietary interventions as a non-pharmaceutical weapon in clinicians' arsenals against infertility. While studies have explored links between general diet/gut microbiota and female reproductive health, the specific relationship between the DI-GM index and female infertility remained unexplored prior to this study. The present cross-sectional study investigates the association between DI-GM, a newly introduced gut microbiota index developed by Kase et al., and female infertility. Study data were obtained from the National Health and Nutrition Examination Survey (NHANES) database (2013–2018) and focused on non-pregnant adult American females (age = 18–45). Kase et al.'s scoring system was used to compute GI-GM scores using all 14 of the index's food and nutritional components. Participant data were obtained via 24-hour dietary recall questionnaires with DI-GM scores ranging from 0 to 13. “The DI-GM includes 10 beneficial components (avocado, broccoli, chickpeas, coffee, cranberries, fermented dairy, fiber, green tea, soy, and whole grains) and four unfavorable components (red meat, processed meat, refined grains, and high-fat diets). Female infertility was assessed using questions (n = 2) from the Reproductive Health Questionnaire (RHQ074 and RHQ076). Additional participant data included demographic, lifestyle, health, and reproductive health details alongside records on infections and inflammatory disease. Of the 29,400 NHANES participants, 14,452 were excluded for being male, 10,625 were excluded for being outside the inclusion age, and 614 were excluded for incomplete information, leaving a final study dataset of 3,053 eligible individuals. Of these, 370 (12.12%) were revealed to be infertile, with infertile participants found to be, on average, older, having a higher body mass index (BMI), married, current smokers, and were more likely to suffer from (or be under treatment for) pelvic diseases or metabolic conditions. Restricted cubic spline plots for the association between DI-GM and infertility in women. Adjusted for age, ethnicity, education level, PIR, marital status, smoking, drinking, dyslipidemia, diabetes, hypertension, menstrual status, PID, birth control pill use, and female hormone use. Logistic regression analyses initially suggested a negative association between DI-GM scores and infertility outcomes when treated as a continuous variable or in quartiles. However, RCS analysis further revealed this association to be non-linear. Below this threshold, higher DI-GM scores were associated with a reduced risk of infertility. “Participants with lower DI-GM scores also exhibited higher triglyceride levels and fasting plasma glucose (FPG) and lower high-density lipoprotein cholesterol (HDL-C) levels (p < 0.05). These observed variations suggest that the potential association between DI-GM and infertility requires further investigation.” Subgroup analysis did not alter these findings, with observed relationships remaining robust demonstrated across a spectrum of subgroups. The present study demonstrates a complex, non-linear relationship between gut microbiota indices (herein DI-GM) and female infertility. While higher DI-GM scores up to a certain point appear protective, very high scores (above 8) were linked to increased risk. This highlights the potential for dietary interventions and future gut microbiota interventions against the rising global concern, emphasizing that achieving a balanced dietary pattern reflected by an optimal DI-GM range, rather than simply maximizing the score, may be key. “As a new dietary quality index that reflects gut microbiota diversity, further research and interventions using DI-GM could help develop strategies to prevent and reduce the risk of female infertility.” Hugo Francisco de Souza is a scientific writer based in Bangalore, Karnataka, India. His academic passions lie in biogeography, evolutionary biology, and herpetology. He is currently pursuing his Ph.D. from the Centre for Ecological Sciences, Indian Institute of Science, where he studies the origins, dispersal, and speciation of wetland-associated snakes. Hugo has received, amongst others, the DST-INSPIRE fellowship for his doctoral research and the Gold Medal from Pondicherry University for academic excellence during his Masters. His research has been published in high-impact peer-reviewed journals, including PLOS Neglected Tropical Diseases and Systematic Biology. When not working or writing, Hugo can be found consuming copious amounts of anime and manga, composing and making music with his bass guitar, shredding trails on his MTB, playing video games (he prefers the term ‘gaming'), or tinkering with all things tech. Please use one of the following formats to cite this article in your essay, paper or report: Gut-linked dietary score reveals surprising risk pattern. Gut-linked dietary score reveals surprising risk pattern". Gut-linked dietary score reveals surprising risk pattern". Gut-linked dietary score reveals surprising risk pattern. Learn how experts are advancing benzodiazepine analysis and detection using insights from the lab. Explore how the Radian ASAP mass spectrometer is being used to streamline and enhance seized drug screening. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. Please check the box above to proceed. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.</p>
                <br/>
                

                <div id='article_title' class='text-3xl text-gray-300 leading-tight'>
                    <a target='_blank' href='https://www.news-medical.net/news/20250504/Semaglutide-clears-liver-inflammation-and-cuts-fibrosis-in-MASH-patients-trial-shows.aspx'>Semaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial shows</a>
                </div>
                <div id='article_attribution'  style='mb-1'>
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Source:</span> {'href': 'https://www.news-medical.net', 'title': 'News-Medical'}&nbsp;&nbsp;&nbsp;
                    <span class='text-1.5xl font-extrabold text-gray-500 leading-tight'>Published:</span> 2025-05-05 01:21:00
                    <i class="fas fa-chevron-down expand-icon text-gray-500" aria-hidden="true"></i>
                </div>
                <p class='hidden' class='text-gray-500'>In an interim analysis of an ongoing global trial, semaglutide resolved steatohepatitis in 63% of patients and reduced liver fibrosis, while also promoting weight loss and improving metabolic health in people with advanced fatty liver disease. Study: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. Globally, over one billion people are estimated to have some form of fatty liver disease. MASH, a progressive form of fatty liver disease, is marked by liver inflammation, hepatocyte injury, and fibrotic changes. Left untreated, it can lead to cirrhosis, liver failure, and hepatocellular carcinoma. MASH is also closely tied to conditions like type 2 diabetes mellitus and obesity. Despite its rising burden, treatment options remain limited, with only resmetirom having received accelerated FDA approval specifically for MASH with significant fibrosis. While lifestyle modification remains first-line, pharmacological interventions have shown mixed results. Given the systemic nature of MASH and its links to cardiometabolic disease, new therapies must target both hepatic and metabolic pathways. Further research is essential to evaluate promising interventions. The present phase 3, randomized, double-blind, placebo-controlled trial was conducted across 253 sites in 37 countries. Participants were randomized in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at 2.4 milligrams or placebo for an initial 72 weeks as part of a longer 240-week trial designed to assess clinical outcomes. Stratification was based on the presence of type 2 diabetes mellitus, fibrosis stage, and geographical region. After an initial dose-escalation period, participants maintained the 2.4-milligram dose unless adverse effects required adjustment. Secondary outcomes included body weight change, composite histological improvement, and change in bodily pain score from the 36-Item Short Form Health Survey (SF-36). Noninvasive markers such as liver stiffness, the enhanced liver fibrosis (ELF) score, FibroScan-AST (FAST) score, N-terminal propeptide of type III collagen (PRO-C3) level, and liver enzyme levels were also monitored. Efficacy analysis followed the intention-to-treat principle and used reference-based multiple imputation for missing data, with adjustments for multiple comparisons. Safety was evaluated through adverse event reporting and laboratory assessments. An external adjudication committee assessed serious clinical events in a blinded fashion. This interim analysis included 800 patients, 534 of whom received semaglutide and 266 of whom were assigned to the placebo group. Baseline characteristics were well balanced, with a mean age of 56 and a mean body mass index of 34.6 kg/m². The resolution of steatohepatitis without worsening of fibrosis was achieved in 62.9% of participants in the semaglutide group compared to 34.3% in the placebo group (difference: 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). Both resolution and fibrosis reduction were observed in 32.7% of the semaglutide group and 16.1% of the placebo group. Weight loss was significantly greater in the semaglutide group, with a mean reduction of 10.5% compared to 2.0% with placebo. Improvement in bodily pain scores did not reach the trial's prespecified threshold for statistical significance. Noninvasive measures also favored semaglutide, with greater reductions in ELF scores and liver stiffness. A 30% or greater reduction in liver stiffness occurred in 52.0% of semaglutide-treated patients versus 30.3% of those on placebo. Semaglutide also improved markers of metabolic health. Glycated hemoglobin levels, insulin resistance as measured by the homeostatic model assessment of insulin resistance (HOMA-IR), high-sensitivity C-reactive protein, and lipid parameters all showed favorable changes. Regarding safety, 86.3% of participants on semaglutide experienced an adverse event compared to 79.7% in the placebo group. Gastrointestinal side effects such as nausea, diarrhea, constipation, and vomiting were more frequent in the semaglutide group but were generally manageable. Serious adverse events occurred at similar rates (13.4%) in both groups, and trial discontinuation due to side effects was low (2.6% vs. 3.3%). While acknowledging limitations such as the small number of Black participants and lack of data on alcohol consumption biomarkers, this interim analysis demonstrates that once-weekly subcutaneous semaglutide at a dose of 2.4 milligrams significantly improves liver histology in patients with MASH and moderate-to-advanced fibrosis. These findings are relevant to a broad population affected by fatty liver disease, obesity, and type 2 diabetes mellitus. The safety profile was consistent with known effects of glucagon-like peptide-1 receptor agonists. Semaglutide presents a promising, multi-targeted therapeutic option for addressing the hepatic and systemic consequences of MASH, though final conclusions on long-term clinical outcomes await the completion of the full trial. His academic journey has allowed him to delve deeper into understanding the intricate world of microorganisms. He has worked on diverse projects in microbiology, biopolymers, and drug delivery. His contributions to these areas have provided him with a comprehensive understanding of the subject matter and the ability to tackle complex research challenges. Please use one of the following formats to cite this article in your essay, paper or report: Semaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial shows. "Semaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial shows". "Semaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial shows". Semaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial shows. Learn how experts are advancing benzodiazepine analysis and detection using insights from the lab. Explore how the Radian ASAP mass spectrometer is being used to streamline and enhance seized drug screening. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. Please check the box above to proceed. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.</p>
                <br/>
                

        </div>

        <script>
            // Get all article attribution elements
            const articleAttributions = document.querySelectorAll('#article_attribution');

            // Add an event listener to each attribution element
            articleAttributions.forEach(attribution => {
            attribution.addEventListener('click', () => {
                // Get the next paragraph element (the article text)
                const articleText = attribution.nextElementSibling;

                // Toggle the visibility of the article text
                articleText.classList.toggle('hidden');

                // Toggle the expand icon
                const expandIcon = attribution.querySelector('.expand-icon');
                expandIcon.classList.toggle('fa-chevron-down');
                expandIcon.classList.toggle('fa-chevron-up');
            });
            });    
        </script>

        <footer class="text-center text-sm text-gray-500 mt-12">
            <div class="inline-block align-middle">
                <a href="https://www.youtube.com/@news_n_clues" target="_blank" rel="noopener noreferrer"
                    class="flex items-center gap-2 text-red-600 hover:text-red-700 font-semibold transition duration-300 ease-in-out">
                    Watch Daily <span class="italic">News'n'Clues</span> Podcast on
                    <img src="../images/yt.png" width="16" height="16">
                </a>
            </div>
            <div>
                <a href="mailto:newsnclues@gmail.com?subject=News'n'Clues Aggregator Inquiry">SoftMillennium
                    <script>document.write(new Date().getFullYear());</script>
                </a>
                <!--
            <b>Copyright &copy; <script>document.write(new Date().getFullYear());</script> - <a href='mailto:newsnclues@gmail.com?subject=News Aggregator Inquiry'>News And Clues</a></b>
            -->
            </div>
        </footer>
    </body>
</html>
            